Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-07

Clinical Trial Update: Daratumumab for the Treatment of Patients With AL Amyloidosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating daratumumab for AL amyloidosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Daratumumab (daratumumab)

Snippet

Sponsor: Boston Medical Center | Conditions: AL Amyloidosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-05-07